Serious ocular adverse events have emerged as a rare but important consequence of MEK inhibitor therapy, thus requiring early ophthalmic screening and subsequent surveillance.17,18 Here we review the ocular adverse events associated with MEK inhibitor therapy for advanced cancers, with a particular focus on MEK inhibitor-associated retinopathy (MEKAR), and share clinical experience and best practice approaches to their management. This evidence concerns the gene MAP2K7 and cancer.